<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03014934</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT-8414113</org_study_id>
    <nct_id>NCT03014934</nct_id>
  </id_info>
  <brief_title>Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>IPAT</acronym>
  <official_title>Impact of Pre-existing Invasive Aspergillosis on Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Acute Leukaemia and Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Via a prospective non-interventional study clinical outcome of patients with - and without -&#xD;
      history of pre-existing invasive aspergillosis undergoing allo-HSCT will be assessed, in&#xD;
      terms of non-relapse mortality overall mortality and fungal infectious morbidity.&#xD;
&#xD;
      Aim. Assessment of 1-year outcome of patients undergoing allo-HSCT with history of&#xD;
      pre-existing IA vs. no pre-existing IA.&#xD;
&#xD;
      Hypothesis. NRM in patients with pre-existing IA is not higher (by a specified margin of 10%)&#xD;
      than patients without pre-existing IA.&#xD;
&#xD;
      Study population. First allo-HSCT in patients with acute leukaemia and MDS given stem cell&#xD;
      grafts.&#xD;
&#xD;
      Cohort 1: History of probable or proven invasive aspergillosis Cohort 2: No History of&#xD;
      probable or proven invasive aspergillosis: this cohort includes also the patient with a&#xD;
      history of possible mycosis not documented microbiologically.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background &amp; Rationale. In patients with pre-existing invasive aspergillosis allo-HSCT is&#xD;
      feasible without progression of fungal infection. However, the influence of invasive&#xD;
      pulmonary aspergillosis (IA) on transplant related complications and on long term survival&#xD;
      has not been investigated in a larger patient cohort under current conditions.&#xD;
&#xD;
      Recently the IDWP and ALWP performed a retrospective analysis on the impact of preexisting&#xD;
      aspergillosis on allo-HSCT outcome.2 In summary, there was a trend towards impaired outcome&#xD;
      of allo-HSCT in patients with prior IA but there was no significant impact on important&#xD;
      allo-HSCT transplant outcomes, such as survival, GVHD and relapse. The data suggest that a&#xD;
      history of IA should not generally be considered a contraindication for allo-HSCT. To be able&#xD;
      to more precisely investigate the impact of IA on allo-HSCT, a non-interventional prospective&#xD;
      study is needed.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To determine if pre-existing IA influences non-relapse mortality after allo-HSCT&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      - To determine if pre-existing IA influences:&#xD;
&#xD;
        -  relapse free survival&#xD;
&#xD;
        -  overall survival&#xD;
&#xD;
        -  incidence and severity of GVHD&#xD;
&#xD;
        -  incidence of relapse&#xD;
&#xD;
        -  incidence of IA post allo-HSCT&#xD;
&#xD;
      for the subgroup of transplant with previous IA&#xD;
&#xD;
      • progression of IA&#xD;
&#xD;
      Research design:&#xD;
&#xD;
      Prospective study. Study recruitment is expected to start by May 1st, 2016. It is expected&#xD;
      that recruitment will be closed by October 31st 2017. Follow up will be till one year after&#xD;
      transplant.&#xD;
&#xD;
      Items:&#xD;
&#xD;
      Data from Med A form, Med C form for all patients, Aspergillus form for patients with&#xD;
      probable/proven IA.&#xD;
&#xD;
      Endpoint(s):&#xD;
&#xD;
      Primary endpoint: 1-year non-relapse mortality cumulative incidence&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  1-year relapse free survival&#xD;
&#xD;
        -  1-year overall survival&#xD;
&#xD;
        -  1-year incidence and severity of GVHD&#xD;
&#xD;
        -  1-year incidence of relapse&#xD;
&#xD;
        -  status of IA (before conditioning and at 1 year)&#xD;
&#xD;
      Study population&#xD;
&#xD;
        -  First allo-HSCT in patients with AML or&#xD;
&#xD;
        -  First allo-HSCT in patients with ALL or&#xD;
&#xD;
        -  First allo-HSCT in patients with MDS&#xD;
&#xD;
      Cohort 1: History of probable or proven invasive aspergillosis Cohort 2: No History of&#xD;
      probable or proven invasive aspergillosis&#xD;
&#xD;
      Cases: Prior IA = probable/proven IA according EORTC 2008 criteria (Cohort 1) Controls: No&#xD;
      prior proven probable IA = all other patients = those really negative for IA and those with&#xD;
      possible IA (Cohort 2)&#xD;
&#xD;
      Sample size Assuming a 20% incidence of non relapse mortality in patients without proven or&#xD;
      probable history of IA, a total of 2100 HSCTs will be needed in order to test the hypothesis&#xD;
      that the incidence of non relapse mortality in cohort 1 (HSCTs with previous history of&#xD;
      proven or probable IA) is not higher than cohort 2 (HSCTs without history of IA or with&#xD;
      previous history of possible IA) by more than a specified margin of 10%. The estimated&#xD;
      proportion of HSCTs in cohort 1 is 5%, thus 105 and 1995 HSCTs will be needed in cohort 1 and&#xD;
      cohort 2, respectively, considering an alpha=0.05, a beta=0.2.&#xD;
&#xD;
      Data Collection &amp; Statistical Analysis Plan:&#xD;
&#xD;
      (List all research variables to be collected and list all outcome variables to be analysed,&#xD;
      give a brief description of the method of analysis (in collaboration with the EBMT&#xD;
      statistician) All data collection will be performed by the IDWP Data Office (Leiden)&#xD;
      according to EBMT guidelines.&#xD;
&#xD;
      Primary endpoint: non relapse mortality The non relapse mortality will be estimated using the&#xD;
      cumulative incidence method. Death due to transplant will be considered as an event, whilst&#xD;
      relapse of the underlying disease will be considered as competing events. Patients alive at&#xD;
      the end of the follow-up will be censored at this date. Cohort 1, vs. Cohort 2 will be&#xD;
      compared by the Gray test.&#xD;
&#xD;
      A cause specific Cox model will be performed in order to estimate the risk of dying for&#xD;
      Cohort 1 respect Cohort 2.&#xD;
&#xD;
      The following variables will enter the multivariate model as possible confounders: age (as&#xD;
      continuous variable), gender (M vs. F), underlying disease (ALL vs. AML/MDS), status at SCT&#xD;
      (1st CR vs. ≥ 2 CR vs. Prim Refr/noCR), time from diagnosis to SCT (as continuous variable),&#xD;
      donor type (sibling vs. UD vs. Haplo), source of SCT (BM vs. PB vs. CB), donor age, d/r&#xD;
      gender match, d/r CMV status, conditioning regimens (MAC vs. RIC vs. TBI), type of&#xD;
      immunosuppression (in vivo T depletion y/n, in vitro T-depletion y/n), DLI post SCT (y/n),&#xD;
      centre.&#xD;
&#xD;
      Secondary endpoints Relapse free survival and overall survival will be estimated by the&#xD;
      Kaplan-Meier methods. Incidence of GvHD and incidence of relapse will be estimated by the&#xD;
      cumulative incidence methods. A cause specific Cox model will be estimated to compare Cohort&#xD;
      1 and Cohort 2; it will be adjusted by the confounders analyzed also in the primary endpoint.&#xD;
&#xD;
      The severity of GvHD will be described by descriptive statistics. Frequencies and percentages&#xD;
      will be use for categorical variables, whilst median, range, mean and standard deviation will&#xD;
      be computed for continuous variables.&#xD;
&#xD;
      Additional descriptive statistic will be separately performed in cohort 2. Main&#xD;
      characteristics of patients will be also described.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>1 year</time_frame>
    <description>One year non-relapse mortality cumulative incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>1 year</time_frame>
    <description>One year relapse free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>One year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Graft versus Host Disease</measure>
    <time_frame>1 year</time_frame>
    <description>One year incidence and severity of Graft versus Host Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>1 year</time_frame>
    <description>One year incidence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of Invasive Aspergillosis</measure>
    <time_frame>1 year</time_frame>
    <description>Status of Invasive Aspergillosis, before conditioning and at 1 year</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Cases: Prior Invasive Aspergillosis</arm_group_label>
    <description>History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls: No prior proven Invasive Aspergillosis</arm_group_label>
    <description>Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        First allo-HSCT in patients with acute leukaemia and MDS given stem cell grafts.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First allo-HSCT&#xD;
&#xD;
          -  Acute leukaemia or MDS&#xD;
&#xD;
          -  Received stem cell grafts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History, in the 6 months preceding HSCT, or documented presence of Invasive candida or&#xD;
             mould infections other than IA (Mucor, Fusariosis).&#xD;
&#xD;
          -  (Previous history Candida infection, both superficial or systemic, is not an exclusion&#xD;
             criteria if the patient has completely recovered from it at HSCT).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Penack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Styczynski</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Collegium Medicum UMK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hoek, MD</last_name>
    <phone>+31715265668</phone>
    <email>j.d.c.hoek@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renate Arnold</last_name>
      <phone>49-30-450-553-302</phone>
      <email>renate.arnold@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute G. Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edoardo Lanino, MD</last_name>
      <phone>39-010-5636-2405</phone>
      <email>edoardolanino@gaslini.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Basso</last_name>
      <phone>39-049-821-3579</phone>
      <email>giuseppe.basso@unipd.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>+39-011-313-5360</phone>
      <email>franca.fagioli@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Aljurf</last_name>
      <phone>(996-1) 442-4586</phone>
      <email>maljurf@kfshrc.edu.sa</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Sierra, MD</last_name>
      <phone>34-93-556-5649</phone>
      <email>tolius@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Baldomero</last_name>
      <phone>+41 61 265 3203</phone>
      <email>Helen.Baldomero@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gazi University School of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulker Kocak, MD</last_name>
      <phone>+90 0312-202-60-15</phone>
      <email>ulkerkocak@gazi.edu.tr</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillosis</keyword>
  <keyword>IA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

